Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General…
| Quarter | Revenue | YoY | Net Income | EPS (dil.) | YoY | Gross Margin | Op. Margin |
|---|---|---|---|---|---|---|---|
| Q1 2026 Mar 2026 | $156.6M | -21.7% | $-121.9M | $-0.69 | -283.3% | -1.0% | -29.6% |
| Q4 2025 Dec 2025 | $253.3M | — | $14.6M | — | — | 31.0% | 14.7% |
| Q3 2025 Sep 2025 | $163.9M | — | $-43.1M | — | — | 0.0% | -27.2% |
| Q2 2025 Jun 2025 | $171.2M | — | $-43.5M | $-0.24 | — | 5.0% | -16.7% |
| Q1 2025 Mar 2025 | $200.0M | — | $-31.6M | $-0.18 | — | 16.6% | -9.9% |
Data from Yahoo Finance. YoY compares the same quarter of the prior fiscal year.
Are the latest Evotec Earnings and an 8% share price surge the start of a real turnaround or just another relief rally? Maik Kemper Editor in Chief We…